Back to Directory

Antigonie Biosciences

Founded 2025
Targeted RNA therapeutics for blood cancers

Antigonie Biosciences is a biopharmaceutical company developing RNA therapeutics for blood cancers. Its Asteria platform is designed to deliver RNA to malignant blood stem and progenitor cells in the bone marrow. The approach uses RNA interference to silence mutations that drive disease, including JAK2 V617F. The company originated from research at the University of York’s Centre for Blood Research.